These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32342981)

  • 1. Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension.
    Li B; Zhang Q; Zhang H; Wang C; Xiu R
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32342981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.
    Shahin Y; Khan JA; Samuel N; Chetter I
    Atherosclerosis; 2011 May; 216(1):7-16. PubMed ID: 21411098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients.
    Borghi C; Acelajado MC; Gupta Y; Jain S
    J Hum Hypertens; 2017 Oct; 31(10):605-610. PubMed ID: 28382958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans.
    Velasco A; Solow E; Price A; Wang Z; Arbique D; Arbique G; Adams-Huet B; Schwedhelm E; Lindner JR; Vongpatanasin W
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H118-24. PubMed ID: 27199121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.
    Coats A; Jain S
    J Hum Hypertens; 2017 Jun; 31(6):376-381. PubMed ID: 28252041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Nebivolol Pharmacology and Clinical Evidence.
    Fongemie J; Felix-Getzik E
    Drugs; 2015 Aug; 75(12):1349-71. PubMed ID: 26177892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW; Lin Y; Pejović V; Bowen L
    Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG; Kuwabara M; Borghi C
    Drugs; 2018 Nov; 78(17):1783-1790. PubMed ID: 30426333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial.
    Espinola-Klein C; Weisser G; Jagodzinski A; Savvidis S; Warnholtz A; Ostad MA; Gori T; Munzel T
    Hypertension; 2011 Aug; 58(2):148-54. PubMed ID: 21646599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol in the treatment of arterial hypertension.
    Olawi N; Krüger M; Grimm D; Infanger M; Wehland M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):189-201. PubMed ID: 31066991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study.
    Sendur MA; Güven GS; Yorgun H; Ateş AH; Canpolat U; Sunman H; Karahan S; Kaya B; Aytemir K
    Anadolu Kardiyol Derg; 2014 Jun; 14(4):363-9. PubMed ID: 24818626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
    Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
    Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
    Battise D; Boland CL; Nuzum DS
    Ann Pharmacother; 2019 Apr; 53(4):402-412. PubMed ID: 30449127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of nebivolol for the treatment of endothelial dysfunction in patients with hypertension: the EDEN registry.
    Masoli O; Redruello M; Baliño NP; Grynberg L; Sonia T; Collaud C; Md LV
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):202-7. PubMed ID: 18287889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension.
    Korkmaz H; Karaca I; Koç M; Onalan O; Yilmaz M; Bilen MN
    Endothelium; 2008; 15(3):149-55. PubMed ID: 18568956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.
    Silva IVG; de Figueiredo RC; Rios DRA
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31337127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.